Literature DB >> 18462449

The skeletal manifestations of the congenital disorders of glycosylation.

D Coman1, M Irving, P Kannu, J Jaeken, R Savarirayan.   

Abstract

The congenital disorders of glycosylation (CDG) are a rapidly expanding disease group with protean presentations. Specific end-organ involvement leads to significant morbidity and mortality, and the skeletal manifestations are often not appreciated, apart from the common association of osteopaenia with CDG-Ia. We performed a literature review of all documented skeletal manifestations in reported CDG patients, revealing a diverse range of skeletal phenotypes. We discuss the possible underlying mechanisms of these skeletal manifestations observed in CDG that are important and frequently under-recognized.

Entities:  

Mesh:

Year:  2008        PMID: 18462449     DOI: 10.1111/j.1399-0004.2008.01015.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  14 in total

1.  Bone Dysplasia as a Key Feature in Three Patients with a Novel Congenital Disorder of Glycosylation (CDG) Type II Due to a Deep Intronic Splice Mutation in TMEM165.

Authors:  R Zeevaert; F de Zegher; L Sturiale; D Garozzo; M Smet; M Moens; G Matthijs; J Jaeken
Journal:  JIMD Rep       Date:  2012-08-22

2.  Human immunodeficiency virus type 1 enhancer-binding protein 3 is essential for the expression of asparagine-linked glycosylation 2 in the regulation of osteoblast and chondrocyte differentiation.

Authors:  Katsuyuki Imamura; Shingo Maeda; Ichiro Kawamura; Kanehiro Matsuyama; Naohiro Shinohara; Yuhei Yahiro; Satoshi Nagano; Takao Setoguchi; Masahiro Yokouchi; Yasuhiro Ishidou; Setsuro Komiya
Journal:  J Biol Chem       Date:  2014-02-21       Impact factor: 5.157

Review 3.  Metabolic manipulation of glycosylation disorders in humans and animal models.

Authors:  Hudson H Freeze; Vandana Sharma
Journal:  Semin Cell Dev Biol       Date:  2010-04-02       Impact factor: 7.727

Review 4.  Golgi glycosylation and human inherited diseases.

Authors:  Hudson H Freeze; Bobby G Ng
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-09-01       Impact factor: 10.005

5.  A novel phenotype in N-glycosylation disorders: Gillessen-Kaesbach-Nishimura skeletal dysplasia due to pathogenic variants in ALG9.

Authors:  Emma Tham; Erik A Eklund; Anna Hammarsjö; Per Bengtson; Stefan Geiberger; Kristina Lagerstedt-Robinson; Helena Malmgren; Daniel Nilsson; Gintautas Grigelionis; Peter Conner; Peter Lindgren; Anna Lindstrand; Anna Wedell; Margareta Albåge; Katarzyna Zielinska; Ann Nordgren; Nikos Papadogiannakis; Gen Nishimura; Giedre Grigelioniene
Journal:  Eur J Hum Genet       Date:  2015-05-13       Impact factor: 4.246

6.  Congenital disorder of glycosylation type Id (CDG Id): phenotypic, biochemical and molecular characterization of a new patient.

Authors:  A Rimella-Le-Huu; H Henry; I Kern; S Hanquinet; E Roulet-Perez; C J Newman; A Superti-Furga; L Bonafé; D Ballhausen
Journal:  J Inherit Metab Dis       Date:  2008-08-09       Impact factor: 4.982

7.  Classical Galactosaemia and CDG, the N-Glycosylation Interface. A Review.

Authors:  Ashwini Maratha; Hugh-Owen Colhoun; Ina Knerr; Karen P Coss; Peter Doran; Eileen P Treacy
Journal:  JIMD Rep       Date:  2016-08-09

Review 8.  Immunological aspects of congenital disorders of glycosylation (CDG): a review.

Authors:  Maria Monticelli; Tiago Ferro; Jaak Jaeken; Vanessa Dos Reis Ferreira; Paula A Videira
Journal:  J Inherit Metab Dis       Date:  2016-07-08       Impact factor: 4.750

Review 9.  Human diseases associated with form and function of the Golgi complex.

Authors:  Mariana G Bexiga; Jeremy C Simpson
Journal:  Int J Mol Sci       Date:  2013-09-10       Impact factor: 5.923

10.  A zebrafish model of PMM2-CDG reveals altered neurogenesis and a substrate-accumulation mechanism for N-linked glycosylation deficiency.

Authors:  Abigail Cline; Ningguo Gao; Heather Flanagan-Steet; Vandana Sharma; Sabrina Rosa; Roberto Sonon; Parastoo Azadi; Kirsten C Sadler; Hudson H Freeze; Mark A Lehrman; Richard Steet
Journal:  Mol Biol Cell       Date:  2012-09-05       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.